56
Views
33
CrossRef citations to date
0
Altmetric
Original Article

A significantly impaired natural killer cell activity due to a low activity on a per-cell basis in rheumatoid arthritis

, , , , , , , , , , , & show all
Pages 245-252 | Received 07 Jan 2009, Accepted 06 Feb 2009, Published online: 02 Jan 2014

References

  • Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood. 1990;76:2421–8.
  • Seaman WE. Natural killer cells and natural killer T cells. Arthr Rheum. 2000;43:1204–17.
  • Lather LL. NK cell receptors. Annu Rev Immunol. 1998;16:359–93.
  • Vivier E, Nunes JA, Vely F. Natural killer cell signaling path-ways. Science. 2004;306:1517–9.
  • Andrade F, Casciola-Rosen LA, Rosen A. Granzyme B-induced cell death. Acta Haematol. 2004;111:28–41.
  • Ida H, Utz PJ, Anderson P, Eguchi K. Granzyme B and natural killer (NK) cell death. Mod Rheumatol. 2005;15:315–22.
  • Takeda K, Dennert G. The development of autoimmunity in C57BL/6 lpr mice correlates with the disappearance of natural killer type 1-positive cells: evidence for their suppressive action on bone marrow stem cell proliferation, B cell immunoglobulin secretion, and autoimmune symptoms. J Exp Med. 1993;177: 155–64.
  • Zhang B, Yamamura T, Kondo T, Fujiwara M, Tabira T. Regu-lation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med. 1997;186:1677–87.
  • Fort MM, Leach MW, Rennick DM. A role for NK cells as regulators of CD4+ T cells in a transfer model of colitis. J Immunol. 1998;161: 3256–61.
  • Flodstrom M, Shi FD, Sarvetnick N, Ljunggren HG. The natural killer cell-friend or foe in autoimmune disease? Scand J Immunol. 2002;55:432–41.
  • Schett G. Review: immune cells and mediators of inflammatory arthritis. Autoimmunity. 2008;41:224–9.
  • Huber LC, Distler 0, Tamer I, Gay RE, Gay S, Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford). 2006;45: 669–75.
  • Sweeney SE, Firestein GS. Rheumatoid arthritis: regulation of synovial inflammation. Int J Biochem Cell Biol. 2004;36:372–8.
  • Shibatomi K, Ida H, Yamasaki S, Nakashima T, Origuchi T, Kawakami A, et al. A novel role for interleukin-18 in human natural killer cell death: high serum levels and low natural killer cell numbers in patients with systemic autoimmune diseases. Arthritis Rheum. 2001;44:884–92.
  • Izumi Y, Ida H, Huang M, Iwanaga N, Tanaka F, Aratake K, et al. Characterization of peripheral natural killer cells in primary Sjögren's syndrome: impaired NK cell activity and low NK cell number. J Lab Clin Med. 2006;147:242–9.
  • Goto M, Tanimoto K, Chihara T, Horiuchi Y. Natural cell-mediated cytotoxicity in Sjögren's syndrome and rheumatoid arthritis. Arthritis Rheum. 1981;24:1377–82.
  • Gonzalez-Amaro R, Alcocer-Varela J, Alarcon-Segovia D. Nat-ural killer cell activity in the systemic connective tissue diseases. J Rheumatol. 1988;15:1223–8.
  • Eguchi K, Ueki Y, Shimomura C, Otsubo T, Nakao H, Migita K, et al. Increment in the Tal+ cells in the peripheral blood and thyroid tissue of patients with Graves' disease. J Immunol. 1989;142:4233–40.
  • Bryant J, Day R, Whiteside TL, Herberman RB. Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Immunol Methods. 1992;146:91–103.
  • Ida H, Nakashima T, Kedersha NL, Yamasaki S, Huang M, Izumi Y, et al. Granzyme B leakage-induced cell death: a new type of activation-induced natural killer cell death. Eur J Immunol. 2003;33:3284–92.
  • Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol. 2001;19:197–223.
  • Lanier LL. On guard-activating NK cell receptors. Nat Immunol. 2001;2:23–7.
  • Biassoni R, Cantoni C, Marras D, Giron-Michel J, Falco M, Moretta L, et al. Human natural killer cell receptors: insights into their molecular function and structure. J Cell Mol Med. 2003;7: 376–87.
  • Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol Biomarkers Prey. 2006;15:2069–77.
  • Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356: 1795–9.
  • Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85.
  • Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observa-tional study. Arthritis Rheum. 2007;56:2886–95.
  • Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692–701.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.